Clinical Trials Browser

Phase 2 × Multiple Myeloma × erdafitinib × Clear all

NCT06308822 2026-03-18

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

Phase 2 Active not recruiting

35 enrolled 9 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT02952573 2020-09-17

Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement

Phase 2 Terminated

Multiple Myeloma, Recurrence